UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

 

FORM 8-K

_____________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): May 18, 2018  

 

Curis, Inc.

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware 000-30347 04-3505116

(State or Other Jurisdiction of

Incorporation)

 (Commission File Number)

(I.R.S. Employer Identification

Number)

     
4 Maguire Road, Lexington, MA 02421
(Address of Principal Executive Offices) (Zip Code)

 

(617) 503-6500

 

(Registrant's telephone number, including area code)

 

Not Applicable

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.

 

(b)

On May 18, 2018, David Tuck, M.D., the Chief Medical Officer of Curis, Inc. (the “Company”), provided to the Company notice of his intention to retire from the Company, effective as of August 31, 2018.

 

On May 23, 2018, Robert E. Martell, M.D., Ph.D. notified the Board of Directors (“Board”) of the Company, that, effective May 31, 2018, he will resign as a member of the Board of Directors. Dr. Martell will join the company as Head of Research and Development on June 1, 2018.

  

Item 8.01.Other Events.

 

On May 24, 2018, the Company issued a press release announcing the appointment of Dr. Martell as Head of Research and Development of the Company and the retirement of Dr. Tuck. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

 

Item 9.01.Financial Statements and Exhibits

 

(d)Exhibits

 

99.1Press release, dated May 24, 2018.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Curis, Inc.  
       
       
Date:  May 24, 2018 By: /s/ James E. Dentzer  
    James E. Dentzer  
    Chief Operating Officer and Chief Financial Officer